Filing Analysis
ALX Oncology Holdings Inc. reported the results of its Annual Meeting of stockholders held on June 10, 2026. The meeting resulted in the election of Class II Directors, approval of executive compensation, and the ratification of KPMG LLP as the independent auditor.
📋 Key Facts
- Annual Meeting of stockholders held on June 10, 2026.
- Election of Class II Directors: Daniel Curran, M.D., Rekha Hemrajani, and Chris Takimoto, M.D., Ph.D. were elected to serve until 2029.
- Advisory vote on executive compensation was approved with 84,540,061 votes 'For' and 13,497,711 votes 'Against'.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 119,293,775 votes 'For'.
ALX Oncology Holdings Inc. announced its financial results for the first quarter ended March 31, 2026. The results were released via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the quarter ended March 31, 2026.
- The report was filed on May 8, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial performance was included as Exhibit 99.1.
- The filing was signed by Harish Shantharam, Chief Financial Officer.
ALX Oncology Holdings Inc. has appointed Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026. Mr. Knight brings over 25 years of experience from companies including Crinetics Pharmaceuticals, Amgen, and Genentech, and will receive a base salary of $565,000 plus 800,000 stock options.
📋 Key Facts
- Jeff Knight appointed as Chief Development and Operating Officer effective April 13, 2026.
- Annual base salary set at $565,000 with a 40% target annual cash bonus.
- Granted a stock option to purchase 800,000 shares under the 2025 Inducement Equity Incentive Plan.
- Mr. Knight previously served as CDOO at Crinetics Pharmaceuticals and held leadership roles at Amgen and Genentech.
ALX Oncology Holdings Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished with the SEC filing.
📋 Key Facts
- Financial results for Q4 and full year 2025 announced on February 27, 2026
- Information furnished under Item 2.02 Results of Operations and Financial Condition
- Press release included as Exhibit 99.1
- Filing signed by CFO Harish Shantharam